These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34908642)

  • 1. Smartphone-based active vaccine safety surveillance (SmartVax) at a Swiss adult vaccination clinic - a pilot study.
    Guedel DS; Peters IJ; Banderet F; Epple V; Egli S; Mehling M; Mayr M; Leeb A; Berger CT
    Swiss Med Wkly; 2021 Dec; 151():w30090. PubMed ID: 34908642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous active surveillance of adverse events following immunisation using SMS technology.
    Westphal DW; Williams SA; Leeb A; Effler PV
    Vaccine; 2016 Jun; 34(29):3350-5. PubMed ID: 27206385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Glover C; Crawford N; Leeb A; Wood N; Macartney K
    Vaccine; 2020 Jun; 38(31):4892-4900. PubMed ID: 32499067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Nyambayo PPM; Gold MS; Mehta UC; Clarke S; Manyevere R; Chirinda L; Zifamba EN; Nyamandi T
    Vaccine; 2023 Oct; 41(45):6700-6709. PubMed ID: 37805357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial.
    Gold MS; Lincoln G; Cashman P; Braunack-Mayer A; Stocks N
    Vaccine; 2021 Jan; 39(2):332-342. PubMed ID: 33279317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using automated text messages to monitor adverse events following immunisation in general practice.
    Leeb A; Regan AK; Peters IJ; Leeb C; Leeb G; Effler PV
    Med J Aust; 2014 Apr; 200(7):416-8. PubMed ID: 24794676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
    Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of live attenuated herpes zoster vaccine in Australian adults 70-79 years of age: an observational study using active surveillance.
    Phillips A; Glover C; Leeb A; Cashman P; Fathima P; Crawford N; Snelling TL; Durrheim D; Macartney K
    BMJ Open; 2021 Mar; 11(3):e043880. PubMed ID: 33766842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination.
    Rahmat H; Leelavathi M; Wan Ismail WF
    Med J Malaysia; 2022 Nov; 77(6):637-642. PubMed ID: 36448378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: A Canadian immunization research network study.
    Psihogios A; Brianne Bota A; Mithani SS; Greyson D; Zhu DT; Fung SG; Wilson SE; Fell DB; Top KA; Bettinger JA; Wilson K
    Vaccine; 2022 Jul; 40(31):4065-4080. PubMed ID: 35680501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana.
    Marfoh K; Samba A; Okyere E; Acheampong F; Owusu E; Darko DNA; Zakariah J; Mensa H; Aidoo E; Mohammed Y
    BMJ Open; 2023 Jun; 13(6):e061643. PubMed ID: 37380201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post COVID-19 vaccination: AusVaxSafety survey participation and adverse events - a community-based regional Queensland study.
    Hamilton E; Oversby S; Kitchener S; Ratsch A
    Aust N Z J Public Health; 2022 Dec; 46(6):738-744. PubMed ID: 36190203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
    Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
    Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using SMS to monitor adverse events following trivalent influenza vaccination in pregnant women.
    Regan AK; Blyth CC; Mak DB; Richmond PC; Effler PV
    Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):522-8. PubMed ID: 25306915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of text-messaging to voice telephone interviews for active surveillance of adverse events following immunisation.
    Regan AK; Blyth CC; Tracey L; Mak DB; Richmond PC; Effler PV
    Vaccine; 2015 Jul; 33(31):3689-94. PubMed ID: 26079616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events following COVID-19 immunisation (AEFI) at a COVID-19 vaccination centre: An observational analytical study.
    Shukla V; Sachan B; Jauhari S; Bhardwaj S; Pathak A; Kandpal SD
    J Family Med Prim Care; 2023 Mar; 12(3):460-465. PubMed ID: 37122665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consumer acceptability and validity of m-Health for the detection of adverse events following immunization - The Stimulated Telephone Assisted Rapid Safety Surveillance (STARSS) randomised control trial.
    Gold MS; Lincoln G; Bednarz J; Braunack-Mayer A; Stocks N
    Vaccine; 2021 Jan; 39(2):237-246. PubMed ID: 33309486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active vaccine safety surveillance of seasonal influenza vaccination via a scalable, integrated system in Western Australian pharmacies: a prospective cohort study.
    Salter S; Singh G; Nissen L; Trentino K; Murray K; Lee K; Kop B; Peters I; Leeb A
    BMJ Open; 2021 Jun; 11(6):e048109. PubMed ID: 34103321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of adverse effects following immunisation degree after the administration COVID-19 vaccine of different platforms.
    Bermawi B; Donastin A; Sari NDK; Kurniasari DW; Adriansyah AA; Ferdiansyah MA; Rofananda IF; Surya PA
    Med J Malaysia; 2024 Mar; 79(2):124-127. PubMed ID: 38553914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.